132 related articles for article (PubMed ID: 35302641)
41. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity.
Sabel MS; Skitzki J; Stoolman L; Egilmez NK; Mathiowitz E; Bailey N; Chang WJ; Chang AE
Ann Surg Oncol; 2004 Feb; 11(2):147-56. PubMed ID: 14761917
[TBL] [Abstract][Full Text] [Related]
42. Oncolytic adenovirus coexpressing interleukin-12 and decorin overcomes Treg-mediated immunosuppression inducing potent antitumor effects in a weakly immunogenic tumor model.
Oh E; Choi IK; Hong J; Yun CO
Oncotarget; 2017 Jan; 8(3):4730-4746. PubMed ID: 28002796
[TBL] [Abstract][Full Text] [Related]
43. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
44. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
45. Strict requirement for vector-induced type I interferon in efficacious antitumor responses to virally encoded IL12.
Melero I; Quetglas JI; Reboredo M; Dubrot J; Rodriguez-Madoz JR; Mancheño U; Casales E; Riezu-Boj JI; Ruiz-Guillen M; Ochoa MC; Sanmamed MF; Thieblemont N; Smerdou C; Hervas-Stubbs S
Cancer Res; 2015 Feb; 75(3):497-507. PubMed ID: 25527611
[TBL] [Abstract][Full Text] [Related]
46. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
47. First-in-Human Phase I Trial of a Tumor-Targeted Cytokine (NHS-IL12) in Subjects with Metastatic Solid Tumors.
Strauss J; Heery CR; Kim JW; Jochems C; Donahue RN; Montgomery AS; McMahon S; Lamping E; Marté JL; Madan RA; Bilusic M; Silver MR; Bertotti E; Schlom J; Gulley JL
Clin Cancer Res; 2019 Jan; 25(1):99-109. PubMed ID: 30131389
[TBL] [Abstract][Full Text] [Related]
48. Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression.
Pavicic PG; Rayman PA; Swaidani S; Rupani A; Makarov V; Tannenbaum CS; Edwards RP; Vlad AM; Diaz-Montero CM; Mahdi H
Oncoimmunology; 2023; 12(1):2198185. PubMed ID: 37066116
[TBL] [Abstract][Full Text] [Related]
49. Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy.
Groeneveldt C; Kinderman P; van den Wollenberg DJM; van den Oever RL; Middelburg J; Mustafa DAM; Hoeben RC; van der Burg SH; van Hall T; van Montfoort N
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33082167
[TBL] [Abstract][Full Text] [Related]
50. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.
Narayanan JSS; Ray P; Hayashi T; Whisenant TC; Vicente D; Carson DA; Miller AM; Schoenberger SP; White RR
Cancer Immunol Res; 2019 Oct; 7(10):1714-1726. PubMed ID: 31409607
[TBL] [Abstract][Full Text] [Related]
51. Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation.
Chen L; Chen H; Ye J; Ge Y; Wang H; Dai E; Ren J; Liu W; Ma C; Ju S; Guo ZS; Liu Z; Bartlett DL
Theranostics; 2021; 11(14):6668-6681. PubMed ID: 34093846
[No Abstract] [Full Text] [Related]
52. Experimental therapy of HPV16 induced tumors with IL12 expressed by recombinant vaccinia virus in mice.
Nemeckova S; Sroller V; Hainz P; Krystofova J; Smahel M; Kutinova L
Int J Mol Med; 2003 Nov; 12(5):789-96. PubMed ID: 14533011
[TBL] [Abstract][Full Text] [Related]
53. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
[TBL] [Abstract][Full Text] [Related]
54. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
55. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
[TBL] [Abstract][Full Text] [Related]
56. SENTI-101, a Preparation of Mesenchymal Stromal Cells Engineered to Express IL12 and IL21, Induces Localized and Durable Antitumor Immunity in Preclinical Models of Peritoneal Solid Tumors.
Gonzalez-Junca A; Liu FD; Nagaraja AS; Mullenix A; Lee CT; Gordley RM; Frimannsson DO; Maller O; Garrison BS; Iyer D; Benabbas A; Truong TA; Quach A; Tian M; Martinez R; Savur R; Perry-McNamara A; Nguyen D; Almudhfar N; Blanco C; Huynh C; Nand A; Lay YE; Magal A; Mangalampalli S; Lee PJ; Lu TK; Lee G
Mol Cancer Ther; 2021 Sep; 20(9):1508-1520. PubMed ID: 34210826
[TBL] [Abstract][Full Text] [Related]
57. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
[TBL] [Abstract][Full Text] [Related]
58. Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using
Liechtenstein T; Perez-Janices N; Blanco-Luquin I; Goyvaerts C; Schwarze J; Dufait I; Lanna A; Ridder M; Guerrero-Setas D; Breckpot K; Escors D
Oncoimmunology; 2014; 3(7):e945378. PubMed ID: 25954597
[TBL] [Abstract][Full Text] [Related]
59. Collagen-Anchored Interleukin-2 and Interleukin-12 Safely Reprogram the Tumor Microenvironment in Canine Soft-Tissue Sarcomas.
Stinson JA; Sheen A; Momin N; Hampel J; Bernstein R; Kamerer R; Fadl-Alla B; Samuelson J; Fink E; Fan TM; Wittrup KD
Clin Cancer Res; 2023 Jun; 29(11):2110-2122. PubMed ID: 37014656
[TBL] [Abstract][Full Text] [Related]
60. Antitumor mechanism of intratumoral injection with IL-12-expressing adenoviral vector against IL-12-unresponsive tumor.
Kanagawa N; Gao JQ; Motomura Y; Yanagawa T; Mukai Y; Yoshioka Y; Okada N; Nakagawa S
Biochem Biophys Res Commun; 2008 Aug; 372(4):821-5. PubMed ID: 18519033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
